How Does Sotatercept Differ From Background PAH Therapies?

The short answer is that sotatercept (Winrevair) targets a different biological pathway involved in how your lung’s blood vessels grow and thicken, whereas your background pulmonary arterial hypertension (PAH) therapies focus largely on relaxing the blood vessels ^[1]. Sotatercept is an approved add-on therapy given by subcutaneous injection every three weeks for adults with PAH ^[2]. While it is not a cure and is not proven to fully correct inherited mutations or reverse existing lung damage in humans, it offers a new way to manage the disease by addressing abnormal cell growth ^[3][4].

Understanding how this medication differs from your current therapies involves looking closely at the underlying biology of PAH.

How Background PAH Therapies Work

The therapies you are currently taking likely fall into categories like endothelin receptor antagonists, PDE5 inhibitors, or prostacyclin pathway therapies ^[5]. These medications can be taken as pills, inhaled, or delivered continuously through an IV or under the skin.

These background therapies are highly effective at improving blood flow and right-heart function ^[5][6]. They work primarily by signaling the smooth muscles around your pulmonary arteries (the blood vessels carrying blood from your heart to your lungs) to relax and widen. However, in PAH, the walls of the pulmonary arteries don’t just tighten—they physically thicken in a process called vascular remodeling ^[1]. Background therapies are not generally considered to directly reverse this established vascular remodeling ^[5][7].

How Sotatercept (Winrevair) Works

Sotatercept works differently because it is designed to influence the biological signals that cause the blood vessels to physically thicken.

In people with PAH, there is an imbalance in a specific communication network inside the body called the BMPR2/TGF-beta pathway ^[1]. While the exact mechanisms are still being studied, researchers propose a “traffic light” model: in PAH, the “green lights” (signals that tell blood vessel cells to multiply) overpower the “red lights” (signals that tell cells to stop growing) ^[1][8]. This imbalance contributes to abnormal cell growth and thickened vessel walls.

Sotatercept acts as a ligand trap ^[1]. It travels through the bloodstream and binds up selected proteins (such as activins) before they can reach the cells, shifting the balance away from abnormal cell growth ^[8][1].

Preclinical studies in laboratories suggest this rebalancing might halt or reduce vascular remodeling ^[9][10]. While structural reversal of the blood vessels has not been proven in human patients, human clinical trials have shown clear benefits. When added to background PAH therapies, sotatercept lowered pulmonary vascular resistance (the resistance to blood flow in the lungs), improved how far patients could walk in six minutes, and reduced the risk of clinical worsening events ^[11][12].

An Add-On Treatment

Because sotatercept and background PAH therapies do two completely different jobs, they are meant to be used together. Sotatercept is prescribed as an add-on therapy for adults (WHO Group 1 PAH) who are already taking background PAH medications ^[12]. You should never stop or change your existing PAH medications without direct instructions from your treating specialist.

Safety, Side Effects, and Monitoring

Because sotatercept modulates biological signaling and blood cell growth, it requires specific monitoring and comes with distinct risks ^[13][2]:

• Bleeding Risks: Patients may experience epistaxis (frequent or severe nosebleeds) or other serious bleeding events ^[12][13]. This risk may be higher if you take blood thinners or prostacyclin therapies. You should contact your doctor urgently if you experience uncontrolled bleeding, coughing up blood, or black/bloody stools.
• Erythrocytosis (Increased Hemoglobin): Sotatercept can cause an abnormally high level of red blood cells (hemoglobin/hematocrit), which thickens the blood and increases the risk of dangerous blood clots ^[12][13].
• Thrombocytopenia: A low blood platelet count, which can further increase bleeding risks ^[12][13].
• Pregnancy Warnings: Sotatercept may cause fetal harm. Patients who can become pregnant must use effective contraception and undergo pregnancy testing before and during treatment ^[2].
• Other Side Effects: Patients may also experience increased blood pressure, dizziness, and telangiectasia (small, widened blood vessels on the skin that look like spider veins) ^[12].

Due to the risks of erythrocytosis and thrombocytopenia, your doctor will check your hemoglobin and platelet counts before you start treatment, during the initial dose-escalation period, and periodically afterward ^[2]. Depending on these blood tests, your care team may need to delay, reduce, or stop a dose of sotatercept.